Company intelligence / Profile preview
Kalos Therapeutics, Inc.
San Diego, California, United Stateskalostpx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Kalos Therapeutics is developing peptides based on the atrial natriuretic peptide family that have demonstrated anti-tumor activity with minimal adverse effects. Their lead compound KTH-222 has shown positive preclinical efficacy results in an in vitro model of pancreatic cancer with no apparent toxicity.
- Therapeutic areas
- Oncology
- Modalities
- PeptidesSynthetic peptide
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Oncology Pharma, Inc.Midwestern University (Glendale, Arizona)
Beyond the preview
Go deeper on Kalos Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kalos Therapeutics, Inc..